arrow
A

Alejandro Martı́n

hospital universitario de salamanca
H指数:46
被引数:8,834

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world CAR-T practice patterns in patients with mantle cell lymphoma: an international survey on behalf of the EBMT lymphoma working party

套细胞淋巴瘤患者中真实世界CAR-T实践模式:EBMT淋巴瘤工作组发起的一项国际调查

2026-08-180
PRE
Durable efficacy and manageable long-term safety of lisocabtagene maraleucel in 3L+ FL: 3-year update from TRANSCEND FL

利萨库特根马拉鲁赛尔在3L+ FL中的持久疗效和可管理的长期安全性:TRANSCEND FL研究3年更新

Blood
IF23.1
2026-07-030
OA
The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL)

IPI风险因素对复发或难治性大B细胞淋巴瘤(LBCL)治疗中CAR T细胞疗法或同种异体干细胞移植的影响

2026-06-190
PRE
Impact of Prior Bendamustine Exposure on Bispecific Antibody Outcomes in Relapsed/Refractory Follicular Lymphoma

Prior Bendamustine Exposure对复发/难治性滤泡性淋巴瘤中双特异性抗体疗效的影响

2026-01-090
OAAI
Laboratory Prognostic Index (LAB-PI) in diffuse large B-cell lymphoma: a single blood analysis predicts outcomes as good as IPI, NCCN-IPI, and GELTAMO-IPI☆

弥漫大B细胞淋巴瘤中的实验室预后指数(LAB-PI):单一血液分析预测结果与IPI、NCCN-IPI和GELTAMO-IPI相当☆

2025-11-250
OAAI
Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3

Brexucabtagene autoleucel 用于 BTKi 初治的复发/难治性套细胞淋巴瘤:ZUMA-2 研究队列 3 的主要分析

Blood
IF23.1
2025-10-310
PRE
Immunological biomarkers of non-infectious complications and overall survival in common variable immunodeficiency

非感染性并发症的免疫学生物标志物及其在共同变异免疫缺陷病中的总生存期

2025-10-300
OAAI
Patient selection and treatment outcomes over time in patients with large B-cell lymphoma receiving car T-cell therapy

大B细胞淋巴瘤患者接受CAR T细胞治疗时的患者选择与治疗结果随时间的变化

2025-09-300
PRE
Maturation-Related and Functional-Associated Phenotypic Profile of Tumor T Cells in Mature/Peripheral T-Cell Neoplasms: Association With the Diagnostic Subtype of the Disease

肿瘤T细胞在成熟/外周T细胞肿瘤中的成熟相关和功能相关表型特征:与疾病诊断亚型的关联

2025-05-180
PRE
Autologous stem cell transplantation for relapsed/refractory large B-cell lymphoma: a multicenter GETH-TC/GELTAMO study

自体干细胞移植治疗复发/难治性大B细胞淋巴瘤:一项多中心GETH-TC/GELTAMO研究

2025-04-030
OA
Site-specific analysis of extranodal involvement in large B-cell lymphoma reveals distinct efficacy with chimeric antigen receptor T-cell therapy

结外受累的大B细胞淋巴瘤的位点特异性分析揭示了嵌合抗原受体T细胞疗法的独特疗效

LEUKEMIA
IF13.4
2025-04-010
PRE
Genetic subtyping by Whole Exome Sequencing across Diffuse Large B Cell Lymphoma and Plasmablastic Lymphoma

通过全外显子测序对弥漫性大B细胞淋巴瘤和浆细胞样淋巴瘤进行遗传亚型分型

2025-03-110
OA
Obesity and overweight in R/R DLBCL patients is associated with a better response to treatment of R2-GDP-GOTEL trial. Potential role of NK CD8+cells and vitamin D
2025-03-040
OAAI
Chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study

嵌合抗原受体T细胞疗法在T细胞/组织细胞丰富的大B细胞淋巴瘤中的疗效及疾病进展后的后续治疗策略:一项GELTAMO/GETH研究

2025-02-040
OAAI
Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma
2024-11-070
OAAI
Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)

ZUMA-2队列3初步分析:在初治布托替尼酪氨酸激酶抑制剂(BTKi)的复发/难治性套细胞淋巴瘤(R/R MCL)患者中应用Brexucabtagene autoleucel(Brexu-Cel)。

BLOOD
IF23.1
2024-11-051
PRE
Enhancing CAR-T Cell Therapy for Non-Hodgkin Lymphoma through Gut Microbiota and Butyrate

通过肠道微生物组和丁酸盐增强非霍奇金淋巴瘤的CAR-T细胞疗法

BLOOD
IF23.1
2024-11-050
PRE
Evolution of Treatment Patterns and Sequencing in Mantle Cell Lymphoma (MCL) in Spain and Their Impact on Survival. the Geltamo-MCL-2022 Study

西班牙套细胞淋巴瘤(MCL)治疗模式与治疗顺序的演变及其对生存的影响:Geltamo-MCL-2022研究

BLOOD
IF23.1
2024-11-050
PRE
Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up

利索卡巴肽马瑞克塞尔(liso-cel)在复发或难治性(R/R)滤泡性淋巴瘤(FL)患者(pts)中的2年随访:超越FL研究

BLOOD
IF23.1
2024-11-050
PRE